- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Cold Agglutinin.
Displaying page 1 of 1.
EudraCT Number: 2009-016966-97 | Sponsor Protocol Number: CAD01 | Start Date*: 2010-06-08 | |||||||||||
Sponsor Name:Universitätsklinikum Essen | |||||||||||||
Full Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease ... | |||||||||||||
Medical condition: Cold agglutinin disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006329-42 | Sponsor Protocol Number: CAD0111 | Start Date*: 2012-10-11 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
Full Title: Short course of Bortezomib in anemic patients with refractory cold agglutinin disease | |||||||||||||
Medical condition: Anaemia with refractory cold agglutinin disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002039-40 | Sponsor Protocol Number: CLNP023L12201 | Start Date*: 2021-10-29 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan (LNP023) in participants with autoimmune benign hematological disorders | ||||||||||||||||||
Medical condition: Immune thrombocytopenia (ITP) Cold agglutinin disease (CAD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) IT (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004835-30 | Sponsor Protocol Number: CAD5 | Start Date*: 2012-10-23 |
Sponsor Name:Department of Medicine, Haugesund Hospital | ||
Full Title: Therapy for chronic cold agglutinin disease: A prospective, non-randomized international multicenter trial on the safety and efficacy of bendamustine and rituximab combination therapy. | ||
Medical condition: Primary chronic cold agglutinin disease requiring treatment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) DK (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005854-90 | Sponsor Protocol Number: ANX005-CAD-01 | Start Date*: 2021-02-11 |
Sponsor Name:Annexon, Inc. | ||
Full Title: A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary... | ||
Medical condition: Primary Cold Agglutinin Disease (CAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003539-12 | Sponsor Protocol Number: EFC16216 | Start Date*: 2017-11-15 | |||||||||||
Sponsor Name:Bioverativ USA Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFU... | |||||||||||||
Medical condition: Primary Cold Agglutinin Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed) ES (Ongoing) BE (Ongoing) NL (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003160-27 | Sponsor Protocol Number: Sobi.PEGCET-101 | Start Date*: 2022-05-31 |
Sponsor Name:Swedish Orphan Biovitrum AB | ||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD) | ||
Medical condition: Patients with Cold Agglutinin Disease (CAD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) NO (Prematurely Ended) HU (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003363-35 | Sponsor Protocol Number: APL2-CP-AIHA-208 | Start Date*: 2018-07-05 | |||||||||||
Sponsor Name:APELLIS PHARMACEUTCIALS, INC. | |||||||||||||
Full Title: An open label, prospective, study to assess the safety, tolerability, efficacy and pharmacokinetics of APL-2 in patients with Warm Antibody Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Di... | |||||||||||||
Medical condition: Patients affected by Warm Antibody Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003538-10 | Sponsor Protocol Number: BIVV009-03 | Start Date*: 2017-11-15 | |||||||||||
Sponsor Name:Bioverativ USA Inc. | |||||||||||||
Full Title: A PHASE 3, PIVOTAL, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION | |||||||||||||
Medical condition: Primary Cold Agglutinin Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed) ES (Completed) BE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003652-22 | Sponsor Protocol Number: INCB50465-206 | Start Date*: 2018-05-18 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia | |||||||||||||
Medical condition: Autoimmune Hemolytic Anemia (AIHA), immunohemolytic anemia, autoimmune hemolytic anemia, immune complex hemolytic anemia. Warm AIHA, Cold AIHA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004998-53 | Sponsor Protocol Number: OMB116024 | Start Date*: 2013-02-05 |
Sponsor Name:National and Kapodistrian University of Athens | ||
Full Title: A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia. | ||
Medical condition: Relapsed or refractory Waldenström’s Macroglobulinemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001033-27 | Sponsor Protocol Number: REMODEL-WM3 | Start Date*: 2016-08-25 |
Sponsor Name:FILO | ||
Full Title: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobuli... | ||
Medical condition: Waldenstrom’s Macroglobulinemia (MW) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000506-37 | Sponsor Protocol Number: ECWM-1 | Start Date*: 2014-10-31 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia | ||
Medical condition: Waldenström's Macroglobulinemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) IT (Ongoing) PT (Prematurely Ended) SE (Ongoing) GR (Restarted) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-005053-20 | Sponsor Protocol Number: ML39235 | Start Date*: 2018-02-06 | |||||||||||
Sponsor Name:Polish Myeloma Consortium | |||||||||||||
Full Title: A multicenter, single-arm, phase II study to evaluate a safety and efficacy of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed/refractory Waldenström Macroglobul... | |||||||||||||
Medical condition: Waldenström's macroglobulinemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002324-36 | Sponsor Protocol Number: MK1026-003 | Start Date*: 2021-03-06 | |||||||||||||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||||||||||||||||||||||
Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies | |||||||||||||||||||||||||||||||||
Medical condition: | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) CZ (Trial now transitioned) HU (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004362-95 | Sponsor Protocol Number: ECWM-2 | Start Date*: 2019-04-12 | |||||||||||
Sponsor Name:University Hospital Ulm | |||||||||||||
Full Title: Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia | |||||||||||||
Medical condition: Waldenström's Macroglobulinemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003563-31 | Sponsor Protocol Number: 26866138CAN 2021 | Start Date*: 2007-03-09 | |||||||||||
Sponsor Name:European Myeloma Network | |||||||||||||
Full Title: Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). | |||||||||||||
Medical condition: Newly diagnosed Waldenstrom's macroglobulinemia (WM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) NL (Ongoing) ES (Ongoing) FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.